PROGNOSTIC VALUE OF HEMATOGONES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA IN FIRST COMPLETE REMISSION
(Abstract release date: 05/21/15)
EHA Library. Hassanein M. 06/12/15; 102589; PB1635
Disclosure(s): Zagazig UniversityMedical Oncology
Mona Hassanein
Contributions
Contributions
Abstract
Abstract: PB1635
Type: Publication Only
Background
Hematogons (HGs) are normal bone marrow cells; that may reflect the quality of the bone marrow response to chemotherapy. Many studies have focused on the role of HGs in acute leukemia.
Aims
In our study, we investigated the prognostic value of HGs expression in patients with AML in first complete remission.
Methods
A total of 65 patients with non- promyelocytic AML, in first complete remission were enrolled in this study, and four color flow cytometry was used to quantify Hematogones. We identify the HGs detectable group as those who had more than or equal to 0.01% HGs in bone marrow aspirated sample.
Results
HGs were detectable in 25 patients’ marrow samples, and they were significantly associated with cytogenetic risk (p=0.01). After a median follow-up of 17.6 months, patients with detectable HGs had better DFS and OS than those with undetectable levels (p=0.013 and <0.001; respectively) and only 3 patients with detectable HGs in marrow remission samples experience relapse. On multivariate analysis, the HG ≥0.01% is an independent predictive value for DFS (p< 0,0001), and OS (p<0,007), but number of chemotherapy cycles to achieve CR and poor cytogenetic had significant prognostic effect on DFS but not on OS.
Summary
we can concluded that AML patients in first complete remission with HGs ≥0.01% have better DFS and OS.
Keyword(s): Myeloid leukemia, Remission
Type: Publication Only
Background
Hematogons (HGs) are normal bone marrow cells; that may reflect the quality of the bone marrow response to chemotherapy. Many studies have focused on the role of HGs in acute leukemia.
Aims
In our study, we investigated the prognostic value of HGs expression in patients with AML in first complete remission.
Methods
A total of 65 patients with non- promyelocytic AML, in first complete remission were enrolled in this study, and four color flow cytometry was used to quantify Hematogones. We identify the HGs detectable group as those who had more than or equal to 0.01% HGs in bone marrow aspirated sample.
Results
HGs were detectable in 25 patients’ marrow samples, and they were significantly associated with cytogenetic risk (p=0.01). After a median follow-up of 17.6 months, patients with detectable HGs had better DFS and OS than those with undetectable levels (p=0.013 and <0.001; respectively) and only 3 patients with detectable HGs in marrow remission samples experience relapse. On multivariate analysis, the HG ≥0.01% is an independent predictive value for DFS (p< 0,0001), and OS (p<0,007), but number of chemotherapy cycles to achieve CR and poor cytogenetic had significant prognostic effect on DFS but not on OS.
Summary
we can concluded that AML patients in first complete remission with HGs ≥0.01% have better DFS and OS.
Keyword(s): Myeloid leukemia, Remission
Abstract: PB1635
Type: Publication Only
Background
Hematogons (HGs) are normal bone marrow cells; that may reflect the quality of the bone marrow response to chemotherapy. Many studies have focused on the role of HGs in acute leukemia.
Aims
In our study, we investigated the prognostic value of HGs expression in patients with AML in first complete remission.
Methods
A total of 65 patients with non- promyelocytic AML, in first complete remission were enrolled in this study, and four color flow cytometry was used to quantify Hematogones. We identify the HGs detectable group as those who had more than or equal to 0.01% HGs in bone marrow aspirated sample.
Results
HGs were detectable in 25 patients’ marrow samples, and they were significantly associated with cytogenetic risk (p=0.01). After a median follow-up of 17.6 months, patients with detectable HGs had better DFS and OS than those with undetectable levels (p=0.013 and <0.001; respectively) and only 3 patients with detectable HGs in marrow remission samples experience relapse. On multivariate analysis, the HG ≥0.01% is an independent predictive value for DFS (p< 0,0001), and OS (p<0,007), but number of chemotherapy cycles to achieve CR and poor cytogenetic had significant prognostic effect on DFS but not on OS.
Summary
we can concluded that AML patients in first complete remission with HGs ≥0.01% have better DFS and OS.
Keyword(s): Myeloid leukemia, Remission
Type: Publication Only
Background
Hematogons (HGs) are normal bone marrow cells; that may reflect the quality of the bone marrow response to chemotherapy. Many studies have focused on the role of HGs in acute leukemia.
Aims
In our study, we investigated the prognostic value of HGs expression in patients with AML in first complete remission.
Methods
A total of 65 patients with non- promyelocytic AML, in first complete remission were enrolled in this study, and four color flow cytometry was used to quantify Hematogones. We identify the HGs detectable group as those who had more than or equal to 0.01% HGs in bone marrow aspirated sample.
Results
HGs were detectable in 25 patients’ marrow samples, and they were significantly associated with cytogenetic risk (p=0.01). After a median follow-up of 17.6 months, patients with detectable HGs had better DFS and OS than those with undetectable levels (p=0.013 and <0.001; respectively) and only 3 patients with detectable HGs in marrow remission samples experience relapse. On multivariate analysis, the HG ≥0.01% is an independent predictive value for DFS (p< 0,0001), and OS (p<0,007), but number of chemotherapy cycles to achieve CR and poor cytogenetic had significant prognostic effect on DFS but not on OS.
Summary
we can concluded that AML patients in first complete remission with HGs ≥0.01% have better DFS and OS.
Keyword(s): Myeloid leukemia, Remission
{{ help_message }}
{{filter}}